Luis Z. Avila, Arlington, MA (US); Clark Q. Pan, Sudbury, MA (US); Patrick Finn, Weymouth, MA (US); John Harrahy, Medway, MA (US); Qun Zhou, Ashland, MA (US); Yunxiang Zhu, Wayland, MA (US); Paul A. Konowicz, Maynard, MA (US); Duncan E. Paterson, Zurich (CH); Andreas Peer, Basel (CH); Joseph P. Kutzko, Southborough, MA (US); Michael R. Reardon, North Attleboro, MA (US); James E. Stefano, Hopkinton, MA (US); Xiaoyang Zheng, Newton, MA (US); Robert J. Miller, E. Bridgewater, MA (US); and Lauren Young, Hampton, NH (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Feb. 14, 2022, as Appl. No. 17/671,249.
Application 16/581,148 is a division of application No. 15/288,486, filed on Oct. 7, 2016, granted, now 10,464,962, issued on Nov. 5, 2019.
Application 17/671,249 is a continuation of application No. 16/581,148, filed on Sep. 24, 2019, granted, now 11,279,725.
Application 15/288,486 is a continuation of application No. 14/445,941, filed on Jul. 29, 2014, granted, now 9,493,498, issued on Nov. 15, 2016.
Application 14/445,941 is a continuation of application No. 13/140,272, granted, now 8,835,614, issued on Sep. 16, 2014, previously published as PCT/US2009/067775, filed on Dec. 11, 2009.
Claims priority of provisional application 61/122,851, filed on Dec. 16, 2008.
Prior Publication US 2022/0242899 A1, Aug. 4, 2022
1. A pharmaceutical composition comprising an oligosaccharide-protein conjugate and an excipient comprising about 10 mM histidine pH 6.5, about 2% glycine, about 2% mannitol and about 0.01% polysorbate 80, wherein the oligosaccharide-protein conjugate comprises: (1) a protein, wherein the protein is acid a-glucosidase, and (2) an oligosaccharide of Formula A:
